1. Faculty of Medicine in Rabigh, King Abdulaziz University, Rabigh, Saudi Arabia.

* Correspondence: 398462967@kau.edu.sa

Keywords: Finerenone, empagliflozin, chronic kidney disease, type 2 diabetes

1. INTRODUCTION

The intertwined epidemics of type 2 diabetes (T2D) and chronic kidney disease (CKD) pose an immense global health burden, representing a leading cause of cardiovascular (CV) morbidity and mortality. Diabetic kidney disease (DKD), the most common cause of end-stage renal disease (ESRD), is characterized by a progressive decline in kidney function and a heightened risk for adverse CV events [1]. For decades, the cornerstone of care has revolved around lifestyle modifications, glycemic optimization, and the use of renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) [4]. These therapies effectively mitigate CV and renal risk by reducing blood pressure and lowering intraglomerular pressure, yet a substantial “residual risk” of disease progression and adverse outcomes persists [5]. This therapeutic plateau stems from a pathophysiological understanding that has evolved beyond a purely hemodynamic view of disease. The progression of cardiorenal disease is a complex interplay of multiple, interconnected pathways, including hyperfiltration, inflammation, and fibrosis. While RAS inhibitors address the hemodynamic component, they do not fully attenuate the underlying inflammatory and fibrotic processes that drive organ damage [1]. This incomplete blockade of the disease cascade necessitates a new, multi-pronged therapeutic strategy. The recent advent of two distinct classes of agents—the non-steroidal mineralocorticoid receptor antagonists (ns-MRAs) and the sodium-glucose cotransporter-2 inhibitors (SGLT2i)—has provided a powerful means to address this critical unmet need [5]. This review aimed to provide a comprehensive analysis of two leading agents from these classes, Finerenone and empagliflozin. By exploring their individual mechanisms of action, the compelling evidence from their respective clinical trials, and the scientific and clinical rationale for their combined use, this report will elucidate a new therapeutic paradigm. The focus is on moving from a traditional stepwise, single-pathway approach to a more proactive, multi-pathway blockade that targets the full spectrum of cardiorenal-metabolic disease.

2. FINERENONE: A TARGETED ANTI-FIBROTIC AND ANTI-INFLAMMATORY AGENT

Finerenone is a structurally novel, non-steroidal mineralocorticoid receptor antagonist (ns-MRA) with a distinct mechanism of action that differentiates it from older, steroidal MRAs like spironolactone and eplerenone [1]. The mineralocorticoid receptor (MR), a ligand-activated transcription factor, is widely distributed in the heart, kidneys, and blood vessels, and its overactivation by aldosterone and other agonists plays a pivotal role in the pathogenesis of cardiorenal disease. While traditional steroidal MRAs are effective, their use in a high-risk CKD population has been limited by a high incidence of adverse effects, particularly hyperkalemia and off-target hormonal effects [13]. Finerenone’s unique pharmacological profile addresses these limitations. It binds to the MR with high affinity and selectivity, yet its binding mode is characterized by a bulky, antagonistic conformation that forms unstable receptor-ligand complexes compared to its steroidal predecessors [8]. This reversible, yet potent, receptor engagement allows it to effectively block the deleterious effects of MR overactivation in target tissues. Furthermore, Finerenone functions as an inverse agonist at the MR, meaning it can reduce the receptor’s basal activity even in the absence of aldosterone. This action further minimizes the expression of pro-fibrotic and pro-inflammatory genes, providing a robust layer of protection against organ damage [1]. At the biochemical level, Finerenone interferes with several downstream signaling pathways. It impedes the aldosterone-dependent nuclear translocation of the MR, a critical step for gene transcription [8]. This conformational change also precludes the recruitment of essential transcriptional co-regulators, such as steroid receptor coactivator-1 (SRC−1). Consequently, Finerenone effectively blocks the upregulation of fibrosis-related genes, such as connective tissue growth factor (CTGF) and lysyl oxidase (LOX), thereby helping to preserve glomerular structure and function. Preclinical studies have also demonstrated that Finerenone’s anti-fibrotic actions include a significant inhibition of profibrotic cardiac tenascin-X (TNX) expression, an effect that is not observed with eplerenone [12]. The high selectivity of Finerenone for the MR minimizes off-target interactions, a feature that contributes to its more favorable safety profile compared to older steroidal agents. The clinical efficacy of Finerenone has been robustly demonstrated in the large-scale FIDELIO-DKD and FIGARO-DKD trials, which enrolled a broad spectrum of patients with CKD and T2D [14]. These trials investigated Finerenone’s effects on top of standard-of-care, including RAS inhibitors, providing crucial evidence for its role in mitigating residual risk [11]. The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial enrolled patients with more advanced CKD, characterized by a lower estimated glomerular filtration rate (eGFR) and severe albuminuria [14]. The primary composite renal endpoint consisted of kidney failure, a sustained decline of ≥40% in eGFR, or renal death.¹⁵ Finerenone demonstrated a significant 3.4% absolute risk reduction (ARR) for this endpoint at 36 months, with a number needed to treat (NNT) of 29 to prevent an event [15]. The treatment effect was primarily driven by a reduction in a sustained decline in eGFR and progression to kidney failure. The trial’s key secondary composite endpoint, encompassing cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke, or hospitalization for heart failure (HHF), also showed a significant benefit, with a 2.4% ARR at 36 months and an NNT of 42. The Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial extended this evidence to a broader population of patients with earlier-stage CKD, including those with moderately elevated albuminuria and a higher eGFR [14]. The trial’s primary endpoint was the same composite CV outcome as the key secondary endpoint in FIDELIO-DKD. Finerenone reduced the risk of this primary composite CV endpoint by a 2.1% ARR at 42 months, with the effect mainly driven by a reduction in HHF [15]. While the secondary renal endpoint did not reach statistical significance in FIGARO-DKD, the trend was directionally favorable. A pooled analysis of both trials, known as FIDELITY, provides a more robust view of Finerenone’s benefits across the cardiorenal continuum of CKD and T2D [16]. This combined analysis strengthens the evidence for Finerenone as a disease-modifying agent that provides broad protection against both renal and cardiovascular events in a wide range of patients with CKD and T2D [17]. The clinical distinction of Finerenone is directly linked to its unique pharmacological properties. The key barrier to the use of older, steroidal MRAs in patients with CKD has been the significant risk of hyperkalemia, an adverse effect that can be life-threatening and frequently leads to drug discontinuation [13]. Finerenone’s non-steroidal structure and reversible receptor engagement translate to a more tolerable safety profile, with a lower incidence of severe hyperkalemia compared to steroidal agents [8]. This safety profile is not merely a beneficial side-effect; it is a fundamental aspect of the drug’s design that allows it to be used more broadly and consistently in a population that stands to benefit the most from its anti-fibrotic and anti-inflammatory effects. This represents a crucial advancement, as it overcomes the primary obstacle that has long limited the use of MRAs in advanced CKD. Furthermore, the patient populations of the FIDELIO-DKD and FIGARO-DKD trials were intentionally distinct, enrolling individuals across a wide spectrum of CKD severity. FIDELIO-DKD targeted patients with lower eGFR and more severe albuminuria, while FIGARO-DKD included those with earlier-stage disease [14]. The fact that Finerenone demonstrated benefits for both renal and cardiovascular outcomes across these different populations indicates that its mechanism of action is effective throughout the disease continuum. This broad applicability simplifies clinical decision-making and reinforces the importance of early intervention. It positions Finerenone as a disease-modifying agent, not just a symptomatic treatment, with the potential to slow progression and preserve organ function by addressing the underlying inflammation and fibrosis that accumulate over time [4].

3. EMPAGLIFLOZIN: A MULTIFACETED HEMODYNAMIC AND METABOLIC AGENT

Empagliflozin is a leading agent in the class of sodium-glucose cotransporter-2 (SGLT2) inhibitors, which were initially developed to treat type 2 diabetes by lowering blood glucose levels [9]. The primary mechanism of action involves the inhibition of the SGLT2 protein, which is in the proximal convoluted tubule of the nephron and is responsible for the reabsorption of approximately 90% of filtered glucose back into the bloodstream [19]. By blocking this protein, empagliflozin promotes the excretion of glucose through the urine, an effect known as glycosuria. This action is independent of insulin, making it a valuable therapeutic option for patients with insulin resistance. While initially appreciated for its glycemic effects, the profound and multifaceted cardiorenal benefits of empagliflozin extend far beyond simple glucose lowering. The co-transport of glucose and sodium by SGLT2 means that its inhibition also leads to a degree of sodium excretion, or natriuresis. This natriuretic effect is a key driver of empagliflozin’s hemodynamic benefits. By increasing the delivery of sodium to the distal tubules, it activates a process called tubuloglomerular feedback, which constricts the afferent renal arteriole [21]. This constriction reduces intraglomerular pressure and hyperfiltration, a major contributor to kidney damage [19]. This leads to a characteristic initial, small, and reversible “dip” in eGFR upon therapy initiation, followed by a slower rate of long-term eGFR decline compared to placebo [2]. Beyond these renal hemodynamic effects, empagliflozin also confers systemic benefits that are crucial for cardiorenal protection. These include improved myocardial energetics through a metabolic shift from glucose to more energy-efficient ketone bodies, reductions in oxidative stress, and direct anti-inflammatory and anti-fibrotic effects [6]. It also has mild diuretic and antihypertensive effects, which further contribute to its cardiovascular benefits, particularly in heart failure [19]. The cardiorenal-protective effects of empagliflozin have been validated in a series of landmark trials that have fundamentally changed clinical guidelines. The EMPA-REG OUTCOME trial, initially a cardiovascular outcomes trial for patients with T2D and established CV disease, was the first to demonstrate these unexpected benefits. It showed a significant reduction in cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The trial also demonstrated that empagliflozin slowed the progression of kidney disease, with treated patients being significantly less likely to experience a rapid decline in eGFR compared to those on placebo [2]. The EMPEROR trials (EMPEROR-Reduced and EMPEROR-Preserved) further solidified empagliflozin’s role in cardiovascular medicine by demonstrating its efficacy in heart failure. The trials showed a significant reduction in HHF and CV death across the full spectrum of heart failure, including both those with reduced and preserved ejection fraction, regardless of their diabetic status [6]. The EMPA-KIDNEY trial provided the most comprehensive evidence for empagliflozin’s renal-protective effects. This groundbreaking trial enrolled a broader population of patients with CKD, including those without diabetes and those with less severe albuminuria. The trial was stopped early due to clear positive efficacy findings, demonstrating that empagliflozin significantly reduced the risk of a composite primary outcome of kidney disease progression or cardiovascular death by 28% compared to placebo [2]. This trial extended the evidence base for SGLT2 inhibitors to a population previously not well-studied, reinforcing their role as a foundational therapy in CKD management. A critical observation from the clinical trials is that the profound cardiorenal benefits of empagliflozin are largely independent of its glucose-lowering effects. The observed reductions in CV events and the slowing of kidney disease progression were consistent across patients with varying levels of glycemic control [6]. This disconnect demonstrates that the primary protective mechanisms are not tied to a reduction in HbA1c, but rather to the drug’s hemodynamic, metabolic, and anti-inflammatory actions [9]. This understanding is essential for clinical practice. It reframes the conversation around SGLT2 inhibitor use, moving them from being perceived as solely “diabetes drugs” to being considered “guideline-directed medical therapy” (GDMT) for cardiorenal protection in patients with CKD and heart failure, regardless of their glycemic status [3]. This insight helps overcome therapeutic inertia and provides a strong rationale for initiating these therapies in patients who may not have high blood sugar but are at high risk for cardiorenal events.

4. THE RATIONALE FOR A COMBINED THERAPEUTIC APPROACH: A TWO-PRONGED ATTACK ON DISEASE PROGRESSION

The clinical success of Finerenone and empagliflozin as monotherapies has led to a natural and compelling hypothesis for their combined use. The core rationale for combining these agents is that they target distinct, yet interconnected, pathophysiological pathways in the progression of cardiorenal disease [7]. A single-agent approach, even with a highly effective drug, may fail to provide comprehensive protection because it cannot fully address the multifactorial nature of the disease. Empagliflozin primarily acts on renal hemodynamics, reducing intraglomerular pressure and hyperfiltration, thereby mitigating kidney injury [19]. Finerenone, on the other hand, targets the non-hemodynamic pathways, specifically by blocking MR-mediated inflammation and fibrosis.¹ A simultaneous blockade of these two pathways offers a synergistic strategy that is theoretically superior to monotherapy alone. By interrupting the vicious cycle of renal damage from both a hemodynamic and an inflammatory/fibrotic perspective, the combination may provide more robust and profound protection, leading to greater long-term benefits [7]. While post-hoc analyses of previous trials, such as the FIDELITY analysis, hinted at the additive benefits of combining an ns-MRA with an SGLT2i, the CONFIDENCE trial was the first prospective, head-to-head randomized controlled trial specifically designed to test this hypothesis [11]. The CONFIDENCE (Combination effect of Finerenone and Empagliflozin in participants with chronic kidney disease and type 2 diabetes) trial demonstrated that the simultaneous initiation of Finerenone and empagliflozin led to a significantly greater reduction in urinary albumin-to-creatinine ratio (UACR), a key surrogate marker for kidney and cardiovascular outcomes, compared to either agent alone. The combination therapy resulted in a 52% reduction in UACR from baseline at 180 days, an effect that was 29% greater than the reduction seen with finerenone alone [27]. Furthermore, 70% of patients in the combination group achieved the American Diabetes Association (ADA) recommended target of a >30% reduction in UACR, compared to only 52% in the monotherapy groups [25]. These findings provide definitive clinical evidence that a dual-pathway approach is superior to a single-agent strategy for reducing kidney damage. Crucially, the safety profile of the combination therapy was favorable. The incidence of symptomatic hypotension, acute kidney injury (AKI), and hyperkalemia leading to drug discontinuation were low [25]. The low rate of hyperkalemia-related discontinuations is particularly notable, as this has historically been the primary concern with MRAs in this patient population. The success of the finerenone and empagliflozin combination in the CONFIDENCE trial is not just a triumph of efficacy but also a solution to a long-standing clinical challenge. The combination may mitigate the primary safety risk of finerenone. The main adverse effect associated with finerenone is hyperkalemia, a risk that is exacerbated in patients with CKD [18]. However, empagliflozin and other SGLT2 inhibitors are known to have a kaliuretic effect, meaning they promote potassium excretion. This counterbalancing effect can help maintain serum potassium levels within a safe range, thereby reducing the incidence and severity of hyperkalemia-related events [21]. The low incidence of hyperkalemia in the CONFIDENCE trial and a meta-analysis showing a small, stable increase in serum potassium with the combination validates this physiological interaction and makes the combination a more practical and safer option for clinicians [25]. The trial’s findings also directly challenge the traditional “stepwise” approach to therapeutic management. In chronic disease, there is often a significant delay, or “therapeutic inertia,” between the identification of a clinical need and the initiation or intensification of therapy. The CONFIDENCE trial demonstrated that a simultaneous, upfront initiation of both agents is not only safe but also leads to a more rapid and profound reduction in albuminuria [27]. Since a greater reduction in UACR is strongly associated with better long-term kidney and CV outcomes, acting early and decisively may prevent irreversible damage that accumulates during a protracted sequential approach.¹¹ This moves the field closer to a “polypill” model of care, which has already revolutionized the management of other chronic conditions like heart failure and hypertension [16]. It is not merely a new therapy, but a new way of delivering therapy that addresses the systemic barriers to optimal care.

5. CLINICAL INTEGRATION AND SAFETY MANAGEMENT

The findings from the landmark trials have rapidly reshaped clinical practice guidelines. The ADA and Kidney Disease: Improving Global Outcomes (KDIGO) consensus statements now recommend a multi-pillared approach to GDMT for patients with CKD and T2D [3]. This framework layers evidence-based pharmacotherapies on a foundation of lifestyle modifications. The pillars include a RAS inhibitor (ACEi or ARB), followed by an SGLT2i, and then a non-steroidal MRA like finerenone [17]. The ADA and KDIGO recommend an SGLT2i with proven cardiorenal benefits for patients with T2D, CKD, and an eGFR ≥20 mL/min/1.73 m2 [17]. Finerenone is recommended for patients with T2D, an eGFR ≥25 mL/min/1.73 m2, a normal serum potassium concentration, and persistent albuminuria (UACR ≥30 mg/g) despite a maximum tolerated dose of a RAS inhibitor. The evidence from the CONFIDENCE trial now supports a departure from a strict sequential approach, especially for patients at high risk, providing a strong rationale for the simultaneous initiation of these agents to overcome therapeutic inertia.A holistic approach to patient management and monitoring is critical when initiating a combination therapy. While the safety profile of the finerenone and empagliflozin combination has been shown to be favorable, clinicians must be vigilant for potential adverse events associated with each agent. The most common adverse effect of finerenone is hyperkalemia, which is a particular concern in patients with reduced kidney function. While empagliflozin’s kaliuretic effect may mitigate this risk, regular monitoring of serum potassium is essential, with baseline and follow-up checks recommended at four weeks after initiation and with any dose changes [17]. Hypotension is another potential side effect of finerenone, though events are typically mild and transient [18]. For empagliflozin, the most common adverse events are urinary tract infections and genital yeast infections, which are a consequence of the drug’s mechanism of increasing urinary glucose excretion. Patients should be educated on the symptoms of these infections and advised on proper hygiene.

Table 01: Landmark Clinical Trials in Cardiorenal-Metabolic Disease

A rare but serious risk is diabetic ketoacidosis, which can occur even in patients with well-controlled blood sugar [31]. Patients should be counseled on the symptoms of ketoacidosis and advised to temporarily stop the medication if they are ill or undergoing surgery [32]. The potential for mild dehydration and symptomatic hypotension should also be discussed, especially in patients who are also taking diuretics. Appropriate patient selection is vital for maximizing the benefits and minimizing the risks of combination therapy. Patients should meet the inclusion criteria of the pivotal trials, with a particular focus on eGFR and UACR thresholds [14]. A baseline assessment of eGFR, UACR, and serum potassium is a necessary prerequisite before initiating therapy. Beyond clinical metrics, patient education and adherence are paramount. Many patients with CKD are asymptomatic in the early stages and may not fully understand the seriousness of their condition [28]. Clinicians should take the time to explain how both therapies work in tandem to protect the heart and kidneys, emphasizing that a proactive approach can slow disease progression and extend the period of event-free survival. This dialogue is essential for fostering patient engagement and ensuring consistent long-term adherence to this new, guideline-directed medical therapy [3].

Table 02: Proposed Therapeutic Management of Combination Therapy

6. CONCLUSION

The formidable burden of cardiorenal-metabolic disease necessitates a therapeutic strategy that extends beyond traditional approaches. The individual pharmacological profiles of finerenone and empagliflozin represent a significant step forward, offering complementary mechanisms of action that target the twin drivers of CKD progression: hemodynamic stress and the non-hemodynamic pathways of inflammation and fibrosis. Finerenone’s potent anti-fibrotic action, enabled by its non-steroidal structure and inverse agonist activity, provides a layer of protection that older MRAs could not safely deliver in this high-risk population. Empagliflozin’s multifaceted hemodynamic and metabolic benefits offer robust cardio-nephroprotection that is largely independent of its glycemic effects. The findings of the CONFIDENCE trial validate the clinical promise of this combination. The study demonstrated that the simultaneous initiation of finerenone and empagliflozin is not only safe but also provides a more profound and rapid reduction in albuminuria than either monotherapy. This evidence supports a move away from a sequential, stepwise escalation of therapy toward a proactive, upfront, multi-pathway blockade. This new paradigm has the potential to overcome therapeutic inertia, prevent irreversible organ damage, and significantly extend event-free and overall survival for millions of patients with CKD and T2D. The combination of finerenone and empagliflozin is poised to become a new standard of care, charting the future of comprehensive cardiorenal protection.

REFRENCES

1. Agarwal R, Green JB, Heerspink HJL, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025;393(6):533–543. doi:10.1056/NEJMoa2410659.
2. Agarwal R, Green JB, Heerspink HJL, et al. CONFIDENCE trial: baseline clinical characteristics. Nephrol Dial Transplant. 2025;40(8):1559–1569. doi:10.1093/ndt/gfaf022.
3. Vaduganathan M, Green JB, Heerspink HJL, et al. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial. Nephrol Dial Transplant. 2025. doi:10.1093/ndt/gfaf160.
4. Vaduganathan M, Green JB, Heerspink HJL, et al. Early hemodynamic safety of simultaneous initiation of finerenone and empagliflozin in CKD and type 2 diabetes: the CONFIDENCE trial. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.02.5081.
5. Agarwal R, et al. Risk of hyperkalemia with empagliflozin, finerenone, or both: secondary analysis of the CONFIDENCE randomized trial. J Am Coll Cardiol. 2026;87(7). doi:10.1016/j.jacc.2025.10.049.
6. Nakhleh A, et al. Real-world effectiveness of finerenone added to SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes and CKD. J Clin Med. 2025;14(22):8209.
7. Antonič M, Adamlje A, Leskovar B, Fornazarič D. Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors. Clin Nephrol. 2025;104:S110–S116. doi:10.5414/CNP104S16.
8. Hanouneh M, Le D, Jaar BG, Tamargo C, Cervantes CE. Real-life experience on the effect of SGLT2 inhibitors vs. finerenone vs. combination on albuminuria in CKD. Diagnostics. 2024;14(13):1357. doi:10.3390/diagnostics14131357.
9. Chuang MH, Wang HY, Kan WC, et al. Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. Nephrol Dial Transplant. 2025;40(10):1897–1905. doi:10.1093/ndt/gfaf064.
10. Wen CF, Chuang MH, Wu VC, Chen JY. Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysis. Front Pharmacol. 2026;17:1803971. doi:10.3389/fphar.2026.1803971.
11. Mortada I, Lee A, Sahu A, Nwaogu C, et al. Additive cardiorenal benefits of finerenone and SGLT2 inhibitor combination therapy in diabetic CKD: a propensity-matched real-world study. Am J Cardiol. 2026. doi:10.1016/j.amjcard.2026.02.035.
12. Tsukamoto S, et al. Cardiovascular and kidney outcomes of combination therapy with SGLT2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and CKD: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022;194:110161.
13. Provenzano M, Jongs N, Vart P, et al. The kidney protective effects of dapagliflozin are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney Int Rep. 2022;7(3):436–443. doi:10.1016/j.ekir.2021.12.013.
14. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. doi:10.1056/NEJMoa2110956.
15. Shrestha S, Shrestha A. Dyslipidemia in Patients with Type 2 Diabetes Mellitus Attending Bir Hospital, NAMS, Nepal. Dinkum Journal of Medical Innovations. 2025;4(09):587–603. doi:10.71017/djmi.4.9.d-0492.
16. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and CKD: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–484. doi:10.1093/eurheartj/ehab777.
17. Rossing P, Anker SD, Filippatos G, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without SGLT2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36–45.
18. Rossing P, Anker SD, Filippatos G, et al. Efficacy and safety of finerenone in patients with CKD and type 2 diabetes by GLP-1RA treatment: subgroup analysis from FIDELIO-DKD. Diabetes Obes Metab. 2022;24(1):125–134.
19. Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33(1):225–237.
20. Ruilope LM, Agarwal R, Anker SD, et al. Blood pressure and cardiorenal outcomes with finerenone in CKD and type 2 diabetes. Hypertension. 2022;79(12):2685–2695. doi:10.1161/HYPERTENSIONAHA.122.19744.
21. Bakris GL, Ruilope LM, Anker SD, et al. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with CKD and type 2 diabetes. Kidney Int. 2023;103(1):196–206. doi:10.1016/j.kint.2022.08.040.
22. Ruilope LM, Pitt B, Anker SD, et al. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023;38(2):372–383. doi:10.1093/ndt/gfac157.
23. Sarafidis P, Anker SD, Agarwal R, et al. Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis. Clin J Am Soc Nephrol. 2023;18(5):602–612.
24. Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with CKD and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437–447. doi:10.1161/CIRCULATIONAHA.121.057983.
25. Filippatos G, Anker SD, Pitt B, et al. Finerenone and heart failure outcomes by kidney function/albuminuria in CKD and diabetes. JACC Heart Fail. 2022;10(11):860–870. doi:10.1016/j.jchf.2022.07.013.
26. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127. doi:10.1056/NEJMoa2204233.
27. Staplin N, Haynes R, Judge PK, et al. Effects of empagliflozin on progression of CKD: a prespecified secondary analysis from the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12(1):39–50. doi:10.1016/S2213-8587(23)00321-2.
28. The EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with CKD: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12(1):51–60. doi:10.1016/S2213-8587(23)00322-4.
29. Herrington WG, Staplin N, Wanner C, et al. Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med. 2025;392(8):777–787. doi:10.1056/NEJMoa2409183.
30. Nangaku M, Herrington WG, Goto S, et al. Effects of empagliflozin in patients with CKD from Japan: exploratory analyses from EMPA-KIDNEY. Clin Exp Nephrol. 2024;28(6):588–595. doi:10.1007/s10157-024-02489-4.
31. Mayne KJ, Sardell RJ, Staplin N, et al. Empagliflozin lowers serum uric acid in CKD: exploratory analyses from the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2025;40(4):720–730. doi:10.1093/ndt/gfae203.
32. Mayne KJ, et al. Frailty, multimorbidity, and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial. Clin J Am Soc Nephrol. 2024. doi:10.2215/CJN.0000000000000498.
33. Tuttle KR, Lakshmanan MC, Rayner B, et al. Safety of empagliflozin in patients with type 2 diabetes and advanced chronic kidney disease. Diabetes Care. 2022;45(6):1445–1452.